+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Uveitis Drug"

From
US Uveitis Market and Competitive Landscape - 2022 - Product Thumbnail Image

US Uveitis Market and Competitive Landscape - 2022

  • Report
  • August 2022
  • United States
From
From
From
Global Uveitis Drugs Market 2022-2026 - Product Thumbnail Image

Global Uveitis Drugs Market 2022-2026

  • Report
  • June 2022
  • 120 Pages
  • Global
From
Global Anterior Uveitis Treatment Market 2022-2026 - Product Thumbnail Image

Global Anterior Uveitis Treatment Market 2022-2026

  • Report
  • March 2022
  • 120 Pages
  • Global
From
From
Global Uveitis Epidemiology and Patient Flow - 2021 - Product Thumbnail Image

Global Uveitis Epidemiology and Patient Flow - 2021

  • Report
  • February 2021
  • Global
From
Uveitis - Epidemiology Forecast to 2029 - Product Thumbnail Image

Uveitis - Epidemiology Forecast to 2029

  • Report
  • June 2021
  • 43 Pages
  • Global
From
From
From
Uveitis - Pipeline Review, H2 2020 - Product Thumbnail Image

Uveitis - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 266 Pages
  • Global
From
Loading Indicator

Uveitis is an inflammatory condition of the eye that can cause vision loss and other complications. Immune disorders drugs are used to treat uveitis and other immune-mediated diseases. These drugs are designed to reduce inflammation and suppress the immune system. Commonly used drugs include corticosteroids, immunosuppressants, and biologics. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunosuppressants are used to reduce the activity of the immune system. Biologics are used to target specific parts of the immune system and reduce inflammation. The uveitis drug market is a rapidly growing segment of the immune disorders drugs market. It is driven by the increasing prevalence of uveitis and other immune-mediated diseases, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more